 | |
| Names | |
|---|---|
| Other names Dynorphin B-13; Rimorphin | |
| Identifiers | |
3D model (JSmol) | |
| ChemSpider |
|
| UNII | |
| |
| |
| Properties | |
| C74H115N21O17 | |
| Molar mass | 1570.8354 |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
Dynorphin B, also known asrimorphin,[2] is a form ofdynorphin and anendogenousopioid peptide with theamino acid sequence Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr (YGGFLRRQFKVVT). Dynorphin B is generated as a proteolytic cleavage product ofleumorphin, which in turn is a cleavage product ofpreproenkephalin B (prodynorphin).[citation needed]
Dynorphin B has an identical N-terminal sequence, but different C-terminal sequence todynorphin A. In an alanine scan of the non-glycine residues of dynorphin B, it was discovered that Tyr1 and Phe4 residues are critical for both opioid receptor affinity and κ-opioid receptor agonist potency, Arg6 and Arg7 promote κ-opioid affinity and Lys10 contributes to the opioid receptor affinity.[3]
Cannabinoid CP55,940 and △9-tetrahydrocannabinol (△9-THC) can induce the release of dynorphin B, which in return acts as anagonist ofκ-opioid receptors, resulting in the production of antinociception.[4] Similarly, Tyr-D-Arg-Phe-Sar (TAPS) is capable of promoting a release of dynorphin B through the simulation ofμ1-opioid receptors, causing a production of antinociception.[5] The antinociceptive effect produced by dynorphin B allows for spinal analgesia.
